Stifel calls United Therapeutics’ (UTHR) topline data from the Phase 3 TETON-2 trial evaluating Tyvaso in idiopathic pulmonary fibrosis patients a “significant upside surprise” and believes the magnitude of the benefit described across multiple TETON-2 endpoints “meaningfully improves the likelihood” of a future Tyvaso approval in this disease setting. The firm, which also believes TPIP has “clearly established a superior clinical profile” compared to Tyvaso, sees Tyvaso efficacy in TETON-2 having a positive read-through for Insmed’s (INSM) TPIP in IPF, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed removed from US Conviction List at Goldman Sachs
- Insmed treatment of Duchenne muscular dystrophy granted orphan designation
- Insmed price target raised to $144 from $126 at Morgan Stanley
- Insmed’s Promising Future: Buy Rating Backed by Brinsupri Approval and Strategic Growth Prospects
- Insmed price target raised to $135 from $111 at JPMorgan